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Abstract
Introduction: monoclonal B-cell lymphocytosis is a symptom free 
condition characterized by the circulation of small clonal population 
of B lymphocytes in peripheral blood (less than 5x109/L) expressing 
an immunophenotype similar to chronic lymphocytic leukemia. 
Different studies based on big hospital series have manifested a higher 
risk in subjects with monoclonal B-cell lymphocytosis to progress to a 
chronic lymphocytic leukemia. The behavior of this hematologic entity 
is unknown therefore its frequency in sporadic chronic lymphocytic 
leukemia patient relatives was determined.
Methods: transversal descriptive study, 8 color flow cytometry was 
performed using two of the tubes of the Euro Flow recommended panel, 
with modifications, for the diagnose of chronic lymphoproliferative 
disorders of B lymphocytes; besides, a fluorescence in situ hybridization 
was performed. univariate and bivariate analyses of the information 
were performed.
Results: monoclonal B-cell lymphocytosis frequency found in 51 
analyzed relatives was 2%, it was a female participant, 59 years old, 
with a total leukocyte count of 7.7x109/L and a B lymphocyte count of 
0.124x109/L; from these, 0.04x109/L were clonal cells with restrictions 
of the kappa light chain. Rearrangements of the IGH gene (14q32) 
were found.
Conclusion: monoclonal B-cell lymphocytosis was detected in one 
relative of a patient with sporadic chronic lymphocytic leukemia in a 
frequency similar to the one reported in general population.
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Resumen
Introducción: La linfocitosis monoclonal de células B es una 
condición asintomática que se caracteriza por la circulación de 
pequeñas poblaciones clonales de linfocitos B en sangre periférica 
(menos de 5x109/L) que expresan un inmunofenotipo similar al de 
la leucemia linfoide cónica. Diferentes estudios basados en grandes 
series hospitalarias, han puesto de manifiesto un riesgo más elevado 
de los sujetos con linfocitosis monoclonal de células B de progresar 
a una leucemia linfoide crónica. En Colombia se desconoce el 
comportamiento de esta entidad hematológica, por tal razón se 
determinó su frecuencia en familiares de pacientes con leucemia 
linfoide crónica esporádica.
Métodos: Estudio descriptivo transversal, se realizó citometría de 
flujo de 8 colores utilizando dos de los tubos del panel recomendado 
por Euro Flow para el diagnóstico de enfermedades linfoproliferativas 
crónicas de linfocitos B con modificaciones, además se hizo 
hibridación fluorescente in situ. Se realizó análisis univariado y 
bivariado.
Resultados: La frecuencia de linfocitosis monoclonal de células B 
encontrada en los 51 familiares analizados fue del 2%, se trató de un 
participante del sexo femenino y 59 años de edad, con un recuento 
total de leucocitos de 7,7x109/L y un recuento de linfocitos B de 
0,124x109/L; de estos 0,04x109/L eran células clonales con restricción 
de la cadena ligera kappa. Se encontraron reordenamientos del gen 
IGH (14q32).
Conclusión: Se detectó linfocitosis monoclonal de células B en un 
familiar de paciente con leucemia linfoide cónica esporádica en una 
frecuencia similar a la informada en la población general.
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Introduction
B Lymphocytes are immune system cells and primary effectors 
of humoral immunity, they specialize on synthesizing and 
secreting immunoglobulins (Ig) and originate from pluripotent 
hematopoeitic stem cells1. Chronic lymphocytic leukemia 
(CLL) was placed in the World Health Organization (WHO)2 
classification among mature B cell neoplasms and characterizes 
by the accumulation of mature B lineage lymphoid cells but 
immunologically incompetent in peripheral blood , bone 
marrow, lymph nodes, spleen and other tissues. Its diagnose, in 
absence of extramedullary tissue infiltration, requires a sustained 
monoclonal lymphocytosis higher to 5x109/L in peripheral blood 
with a characteristic immunophenotype when evaluated with flow 
cytometry which consists of positive CD19, weak CD20, aberrant 
co-expression of CD5, CD23 and weak expression of surface 
immunoglobulyns3-5.
Chronic lymphocytic leukemia causes are unknown, nevertheless 
it is known that the existence of family history is one of the risk 
factors which dispose to suffer this disease6. First-degree relatives 
of patients with pathology have 7.5 times more risk than general 
population to suffer this or other lymphoid neoplasias7, and in 
other cases, and in general population, it is possible to demonstrate 
by flow cytometry the presence in peripheral blood of a clonal 
population of B lymphocytes, a condition known as monoclonal 
B-cell lymphocytosis (MBL)8.
Monoclonal B-cell lymphocytosis  is an entity characterized 
by the presence of clonal populations of B lymphocytes in 
peripheral blood in a proportion minor to 5x109/L3, in subjects 
that do not present clinical signs or symptoms of a B cell chronic 
lymphoproliferative disorder9. According to current classification, 
there are two types of MBL, CLL and non-CLL type; being CLL 
type the most frequent (75 % of the cases)9. In this last one, clonal 
B cells present immunophenotypic characteristics identical to 
the ones observed in CLL and previously described. It has been 
found that in MBL CLL type the number of circulating cloned B 
cells may vary allowing a sub classification in clinic MBL (cMBL) 
and low count MBL. The first is characterized by the presence of 
lymphocytosis and a clonal B cell concentration equal or higher 
to 1.5x109/L; and the second is detected during screening studies 
using sensitive techniques, and it has a clonal B cell count minor 
to 0.05x 109/L9.
Several studies have reported variable MBL prevalence highly 
depending on the characteristics of the examined population and 
the detection methods used for its identification; it is estimated 
that approximately 10 to 15% of people with lymphocytosis have 
MBL10. Prevalence in adults in general (without including those 
with family history of CLL) oscillates between 0.12 and 14.3%11. 
Studies performed in healthy population using two channel 
fluorescence cytometry detected an MBL prevalence of 0.12%12, 
studies using four fluorochromes informed a prevalence of 3.5 to 
3.8%13,14, and those researches with five and eight colors reported 
7.7 % and 12.0% respectively9,15. When studying people with 
familial CLL (condition characterized by the presence of two or 
more people with diagnosed CLL in the same family) prevalences 
are high independently the flow cytometry technique used, 
for example, Rawstron  et al.16, used four color flow cytometry 
and identified, MBL in 13.5% of relatives in the first degree of 
consanguinity with patients with this type of CLL. It was also 
possible to establish the increment in the MBL cases while the age 
of the studied people increases13,15. Based on these reports it has 
been possible to identify four parameters as the most determinant 
of the prevalence of MBL: a) first, the presence or absence of 
absolute lymphocytosis; second, the age of the people subjected 
to study; third, the detection sensitivity of the flow cytometry 
technique used; and fourth, the presence or absence of CLL in the 
family history17.
Several studies based on large groups of hospital patients of 
CLL18,19  have shown a higher risk of MBL subjects to become 
CLL patients. Proof this is the prospective cohort research by 
Landgren et al.19, which demonstrated the hypothesis that CLL is 
always preceded by MBL. In this one, B cell clones were detected 
in 44 out of 45 samples (98%) of cryopreserved lymphocytes 
obtained in blood of subjects without cancer to whom CLL was 
later diagnosed. This precursor state lasted from 6 months to 6 years 
before leukemia developed. No reports providing data on MBL 
epidemiology and dynamic were found in Colombia, therefore the 
behavior of this hematologic entity in the country, and in particular 
in Medellín, is unknown. Hematopoietic origin cancer (leukemias 
and myelomas) occupied the ninth position in morbidity between 
2007 and 2009 in Antioquia, with a gender distribution slightly 
higher in men, to whom 53% of cases were attributed20; besides, 
leukemias were among the first ten dead causes in the 18 to 24 year 
old group21. Thus it is important to know the MBL frequency in 
relatives of sporadic CLL patients assisted in health institutions in 
Medellín, and to know their clinical and biological characteristics; 
this would permit a following of this group and to take preventive 
and control measures which would lead to an early diagnose of 
a lymphoproliferative disorder. The following work determined 
monoclonal B-cell lymphocytosis frequency in sporadic chronic 





A non probabilistic sample of convenience was performed in 51 
relatives in the first and second-degree of consanguinity of 15 
patients diagnosed with CLL, These were obtained during the 9 
months stipulated for sample collection. Each patient filled out 
a survey to obtain epidemiologic and clinical data which would 
allow to verify the accomplishment of the selection criteria. 
Inclusion criteria were: men and women older than 18 years, 
who were relatives in the first or second degree of consanguinity 
of patients diagnosed with sporadic CLL without considering 
the stage that were not diagnosed nor presented symptoms of 
infectious, immunologic diseases or any kind of cancer. The 
exclusion criteria were the people who did not accept nor signed 
the informed consent.
B-cell lymphocytosis detection
The following diagnose criteria were used22:
1) Detection of a monoclonal B-cell population in the peripheral 
blood with light chain restriction
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2) Presence of a disease-specific immunophenotype
3) Absolute B-cell count less than 5 x 109/L
4) No other features of lymphoproliferative disorder (no lymph 
nodes, spleen and/or liver enlargement, no B-symptoms, such
as fever, weight loss or nighttime sweating)
5) No autoimmune or infectious disease .
Flow cytometry
Ten mililiter of EDTA (Ethylenediaminetetraacetic acid) 
anticoagulated peripheral blood were taken, automated Complete 
blood count and flow cytometry analysis using two of the 
tubes (1 and 2) of the panel recommended by Euro Flow for 
the diagnose of chronic B-cell lymphoproliferative disorders23 
with some modifications were performed: (i) CD20-V450, 
CD45-V500c, smIgλ-fluorescein isothiocyanate (FITC), smIgk-
Phycoerythrin (PE), CD5-peridinin-chlorophyll-protein-R-
Phycoerythrin cyanine 5.5(PERCPCY5.5), CD19- Phycoerythrin 
cyanine 7(PECY7), smCD3-Allophycocyanin (APC), CD38-
Allophycocyanin H7(APCH7); (ii) CD20-V450,  CD45-V500c, 
CD23-fluorescein isothiocyanate (FITC), CD10-Phycoerythrin 
(PE), CD19-Phycoerythrin cyanine 7(PECY7), CD200- 
Allophycocyanin (APC), CD43-Allophycocyanin H7(APCH7) 
(Becton Dickinson Biosciences, BDB). Sample was washed using 
300 μL of total blood with 10 mL of buffer BSA (BDB), and after 
this process 50 μL of washed and suspended blood were taken 
and mixed with the volume corresponding to each monoclonal 
antibody according to the manufacturer. Data acquisition was 
performed on a FACSCanto II flow cytometer (BDB), with 
previous quality control with pearls CS&T (BDB) to control de 
cytometer functioning and to control standardization to verify 
readings were made inside the corresponding fluorescence range. 
Analysis was made in two consecutive steps. In the first step 
information corresponding to the total cellularity of the sample 
1x105  cells approximately was stored, while in the second step 
only the information corresponding to B lymphocytes selected 
through an enriched window of CD19+ and/or CD20+ cells was 
stored, until acquiring the maximum possible number of events. 
A positive value higher to 30%24  was considered for the CD38 
analysis. Data analysis was performed using computer software 
Infinicyt by Cytognos.
Fluorescence in situ hybridization (FISH)
Cytogenetic analysis was performed in the sample compatible 
with B cells monoclonal lymphocytosis by flow cytometry; 
EDTA anticoagulated peripheral blood was sent to a laboratory 
of cytogenetic were FISH was done using the following probes: 
Vysis LSI ATM (11q22.3) Spectrum Orange Probe; Vysis LSI TP53 
(17p13.1) Spectrum Orange Probe; Vysis LSI D13S25 (13q14.3) 
Spectrum Orange Probe; Vysis 13q34 Spectrum Green FISH Probe 
Kit; CEP 12 Spectrum Orange Direct Labeled Fluorescent DNA 
Probe Kit; Vysis LSI IGH Dual Color, Break Apart Rearrangement 
Probe (Abbott Molecular); all these intended to detect deletions 
in 11q22.3, 13q14.3 and 17p13.1, rearrangement on 14q32 and 
trisomy 1225.
Statistical analysis
To describe gender, age and complete blood count parameters 
(univariate analysis) summary and measures and frequencies were 
calculated; to compare total leukocyte and lymphocyte counts with 
variables such as gender, kinship, current disease, disease history 
and medicine consumption (bivariate analysis) Mann-Whitney’s 
U test was used, with previous verification of non-accomplishment 
of normality presumption by means of ShapiroWilk’s test. Data 
was stored and analyzed with software SPSS®  version 19.0, 
significant p values lower to 0.05 were considered in all analyses.
Ethical consideration
The project was approved by the Ethic Committee of the Faculty of 
Dentistry of the University of Antioquia. The process of inclusion 
and voluntary participation of subjects was done according to 
national parameters (Resolution N° 008430 October 4 1993, 
Republic of Colombia, Health Minister Office) considered of 
minimal risk, and international (Helsinki Declaration and 
amendments, World Medical Association (WMA), Edinburgh, 
Scotland, October 2008), by which informed consent of all 
participants and patients with CLL was obtained and right to 
autonomy and confidentiality was respected.
Results
Study group characteristics
Twenty participants (39.2%) were men and 31 (60.7%) women, 
with an average age of 47.3±10 and a range between 26 and 66 
years; 30% of the studied people were brothers or sisters of the 
patient with CLL, while 70% were sons or daughters. Leukocyte 
average in the studied participants was 7.32 ±1.78x109/L (range= 
4.8-12.85x109/L); total lymphocytes showed an average of 
2.43x109/L (range= 0.99-4.5x109/L). When comparing total blood 
tests results, significant differences were found (p= 0.030) in the 
total number of leukocytes in men and women, with significant 
higher values in women, this same was observed in the count of 
lymphocytes and platelets; nevertheless, no significant differences 
were found in the hematological variables when compared 
by kinship, current disease, disease history and medicine 
consumption. When studying the CD38 expression percentage 
in B lymphocytes in the study group, a mean expression of 15% 
(range= 2.6%-35.3%).
Monoclonal B-cell lymphocytosis frequency
Monoclonal B-cell lymphocytosis was detected in one (2%) out of 
the 51 relatives analyzed, it was a 59 year old female participant 
with a total leukocyte count of 7.7x109/L and B lymphocyte count 
of 0.124x109/L; out of these 0.04x109/L were clonal cells with 
kappa light chain restriction. CD38 expression in the cells of this 
participant was 6%. It was classified as low-count CLL-like MBL.
Cytogenetic alteration detection with FISH
When detecting cytogenetic alterations in participants with MBL, 
rearrangement on 14q32 was found in 43% of the analyzed cells 
but neither deletions in 11q22.3, 13q14.3 and 17p13.1, nor trisomy 
12 were detected.
Discussion
Monoclonal B-cell lymphocytosis frequency found in this research 
was 2%, which is lower to what has been reported in literature in 
studies performed in healthy people with familial CLL history. 
for example, Marti et al.26, reported MBL in 18 % while Lanasa et 
al.27, analyzed 622 people and their data was 16.2%. These reports 
could explain the lower frequency in the current work, mainly 
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related with the kind of sporadic CLL in the families in Medellin. 
General rates of MBL among relatives of patients with this kind 
of leukemia may be compared to general population, but relatives 
older than 60 years show a higher risk of MBL, similar to what 
was observed in non-affected individuals from families with 
familial CLL 28. This suggests that MBL in these families represents 
an inherited predisposition to CLL and that both entities share 
factors of genetic origin. Increment in the risk of these relatives 
indicates CLL phenotype cells represent a surrogate marker of the 
carrier status18.
Another aspect to consider with the frequency found is the age of 
the study group, as most of the analyzed subjects were between 40 
and 50 years old and only 10% were older than 60 years. It has been 
reported that MBL behaves similar to CLL in older people. Nieto et 
al.15, demonstrated that clonal B cells progressively incremented 
with age, being in people older than 90 years was 75%. Some 
researchers consider MBL could represent a normal aspect of the 
immune system, especially of the immunosenescence process due 
to the high frequency of the entity in older people which is 100 
times higher than CLL’s one9.
Due to the low frequency of the event, the current work could 
neither study prevalence of subgroups nor explore possible 
associations between variables and the hematologic entity, 
nevertheless it is important to mention the positive case for MLB 
was female gender. Different to CLL, in which male-to-female 
ratio is 2:129, studies in MBL have not been conclusive in that 
respect. Results of a meta analysis of MBL prevalence30  did not 
show significant differences in the risk to suffer MBL between 
men and women, and it was found that only in those works 
including people with other diseases there was a higher prevalence 
in women, which could not be attributed to gender but to the 
base disease. Unfortunately, included researches did not explore 
the possible confusing effect of gender, which would improve the 
internal validity of these and the quality of the conclusions related 
with this association.
Regarding the subtypes of MBL described in literature, low-count 
CLL-like MBL was detected; based in number and clinical criteria, 
this is a clearly different entity of clinic MBL, even though they 
share the characteristic phenotype. This intrinsic difference is also 
supported by the few studies on its biological characteristics when 
little populations of B cell like CLL in peripheral blood have been 
isolated and analyzed31. According to what has been reported up to 
now in literature, in low count MBL there is overrepresentation of 
IGHV4-59/61 genes and increment in the presence of these genes 
has also happened in people with advanced age, which suggests 
it could simply reflect restriction of repertoire related with age 
in healthy individuals. This supports even more the chance that 
this subtype may simple represent one aspect of the physiologic 
process of immunosenescence. Repertory similar restrictions are 
well established for the peripheral pool of T cells, when diversity 
of T cell receptor (TCR) seems to collapse with age32.
Chromosomal alteration detected in the relative with MBL was 
14q32 rearrangement, which implies Ig heavy chain; This has been 
mainly described in multiple myeloma, nevertheless several studies 
have reported it with more and more frequency in CLL patients. 
The rearrangement consists in complex and heterogeneous 
translocations with the breakpoint involving either the switch of 
IGH or the V, D or J gene. The primary translocations are due to 
somatic hyper mutation or errors in the VDJ portion of the switch 
region recombination. The translocations include a promiscuous 
array of at least 20 nonrandom chromosomal partners and the 
characterization of these translocations has led to the identification 
of critical deregulated oncogenes (e.g. BCL2, cyclin D). In each 
translocation, a potent enhancer is juxtaposed to deregulated 
oncogenes. The most frequent IGH translocations include t(4; 14) 
(p16.3; q32.3), t(11; 14) (q13; q32.3) and t(14; 16) (q32.3; q23)33. 
Due to the kind of probe used for the cytogenetic analysis (Vysis 
LSI IGH Dual Color, Break Apart Rearrangement Probe), which 
provides valuable information on the gene rearrangement, but 
does not specify the partner with which translocation occurred, 
analysis of this finding in our participant becomes harder. When 
reviewing literature, we did not find reports of this disorder in low 
count MBL, nevertheless it has been detected in multi clonal cases 
of clinic MBL and in monoclonal and multi clonal CLL cases34. 
A similar behavior was reported in another work of Henriqueset 
al.35, in which this kind of low count MBL disorder was not 
detected, but was in high count MBL and CLL. This cytogenetic 
disorder has also been reported in negative CD5 MBL and 
marginal zone lymphoma36. Kern et al.37, did not find significant 
statistical differences in the presentation of this translocation 
when comparing MBL cohorts (do not specify subtype) and 
CLL. Although this translocation is considered unfavorable CLL 
prognosis38, it is not possible, as it is in most cytogenetic disorders 
of CLL prognosis value, to interpolate the MBL results, specifically 
because of the few studies where an analysis of this is done and 
because it is still considered of low frequency. There is agreement 
in that gradual acquisition of genetic disorders may determine 
the progress rate, not only from high count MBL to CLL, but also 
form low count MBL to high count MBL and finally CLL34. The 
concurrence of chronic anti genetic stimulation by specific B cell 
receptors (BCRs) may increase and accelerate the expansion of 
MBL clones, facilitate the acquisition of new genetic disorders and 
contribute to the progress of CLL39.
When it comes to clinical management of individuals with MBL, 
this is different according to the characteristic subtype of the 
entity. In pragmatic terms, the general physician could follow 
up people with low count MBL, due to these individuals have a 
completely normal blood count and clinical experience have 
demonstrated in particular that progression of this group is very 
rare. Close surveying is not necessary for this kind of people and a 
yearly complete blood count test is enough and appropriated40. The 
participant to whom MBL was detected was recommended yearly 
checkups with the hematologist co researcher of the current work 
and a total blood count to monitor total lymphocyte concentration 
in peripheral blood.
It must be considered that the external validity of this study presents 
limitations due to it was not possible to calculate the size of the 
sample and perform probability sampling because, among other 
factors, of the lack of data in the country, and even Latin America, 
on the expected influence of the event, as well as the absence of 
an adequate sampling frame of the patients in Medellin. Despite 
these limitations, this work constitutes a first approximation to 
the frequency of this entity in Colombia and provides initial ideas 
and directions to further research which is necessary especially if 
population subgroups, such as CLL patient relatives, are studied.
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